Drugs targeting the LPL pathway under investigation for NAFLD include the angiopoietin-like protein-3 (ANGPTL3) inhibitors,35 glucagon-like peptide-1 (GLP-1) receptor agonists,36 and dual glucose-dependent insulinotropic peptide (GIP)/GLP-1 receptor agonists.37 Here, ANGPTL3 is linked to metabolic dysfunction-associated steatotic liver disease.